Skip to main content
Premium Trial:

Request an Annual Quote

LunaDNA, Genetic Alliance to Merge Technology Platforms

NEW YORK (GenomeWeb) – LunaPBC, the public-benefit corporation that operates the LunaDNA genomic data platform, today announced plans to merge its technology with nonprofit health advocacy organization Genetic Alliance's patient engagement platform.

Solana Beach, California-based LunaPBC said that the two organizations would spend much of 2019 intertwining Genetic Alliance's offering, called the Platform for Engaging Everyone Responsibly, with LunaDNA in an effort to support improved health management and to provide individuals and communities with more research opportunities.

Last month, startup LunaDNA received approval from the US Securities and Exchange Commission to to recognize personal health data, including genomes, as a form of currency. That gave the organization the go-ahead to open its technology platform to US residents wishing to contribute their medical and DNA data in exchange for shares in the community-owned platform.

Similarly, Washington-based Genetic Alliance, which dates to 1986, offers individuals control over their own health data for research purposes.

"Like us, [LunaPBC believes] individuals need and deserve opportunities to be active participants in their own health and research opportunities. The day of de-identified data is over," Genetic Alliance President and CEO Sharon Terry said in a statement.

"Together, we're providing a people-centric model that empowers the individual to offer access to their health data and also receive support. We are building secure and transparent communities and connections geared towards supporting the individual that will accelerate medical breakthroughs," Terry continued.

"By putting people truly at the center of the model versus just leveraging them as sources of specimens, we engage individuals as true partners in creating a dynamic, real-world asset for research," LunaPBC President and Cofounder Dawn Barry added. "Rather than having researchers wait for sufficient data to pose questions, the community-owned data is poised to address their novel hypotheses."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.